Compare NFG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | TGTX |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.5B |
| IPO Year | 1997 | 2008 |
| Metric | NFG | TGTX |
|---|---|---|
| Price | $78.90 | $52.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $102.00 | $49.80 |
| AVG Volume (30 Days) | 656.0K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | 576.19 | ★ 1746.67 |
| EPS | ★ 4.58 | 0.12 |
| Revenue | ★ $2,277,541,000.00 | $2,785,000.00 |
| Revenue This Year | $15.04 | $49.08 |
| Revenue Next Year | $23.44 | $26.69 |
| P/E Ratio | ★ $16.93 | $446.04 |
| Revenue Growth | ★ 17.11 | N/A |
| 52 Week Low | $75.17 | $25.37 |
| 52 Week High | $97.06 | $57.38 |
| Indicator | NFG | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 65.27 |
| Support Level | $77.51 | $28.57 |
| Resistance Level | $78.90 | $57.38 |
| Average True Range (ATR) | 1.27 | 2.37 |
| MACD | 0.49 | -0.12 |
| Stochastic Oscillator | 95.99 | 50.17 |
National Fuel Gas Co is a diversified energy company involved in natural gas production, gathering, transportation, distribution, and marketing. It operates through three segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. The majority of revenue comes from the Integrated Upstream and Gathering segment, which focuses on Seneca's natural gas exploration and development in the Appalachian region and Midstream operations supporting gas processing and gathering. The Pipeline and Storage segment transports and stores natural gas for customers in the northeastern United States and Canada, while the Utility segment supplies natural gas to retail customers in western New York and northwestern Pennsylvania. the company opeartes in United States.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.